DTP vaccine withdrawal
Executive Summary
Connaught Labs' Feb. 23 withdrawal of its diptheria-tetanus-pertussis vaccine adsorbed lot number 8M91039 was initiated after a routine quality assurance inspection. Connaught said it "determined that four vials of Inflogen, an inactivated equine influenza vaccine, in storage at the plant were incorrectly labeled as DTP." The company is coordinating withdrawal activities with FDA. The lot contained 45,909 vials, approximately 19,083 of which were shipped to 1,865 doctors, pharmacists and distributors. Each is being contacted by telephone and telegram, Connaught said. The firm added that there is no evidence that any vials containing Inflogen left the plant.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.